Ones To Watch News
Refine Search
Biotechnology
Swiss-American biotech CRISPR Therapeutics and USA-based Capsida Biotherapeutics have entered into a strategic partnership to research, develop, manufacture and commercialize in vivo gene editing therapies delivered with engineered AAV vectors for the treatment of familial amyotrophic lateral sclerosis (ALS) and Friedreich’s ataxia. 15 June 2021
Biotechnology
UK pharma major GlaxoSmithKline has entered into a collaboration with Belgian biotech iTeos Therapeutics to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody (MAb) currently in Phase I development as a potential treatment for patients with cancer. 14 June 2021
Biotechnology
US biotech Protagonist Therapeutics saw its shares gain 17% to $39.64 on Friday, after it announced updated results from the ongoing Phase II study of rusfertide (PTG-300), an investigational new drug being evaluated for the treatment of polycythemia vera (PV), a type of blood cancer. 12 June 2021
Biotechnology
Irish immuno-oncology specialist ALX Oncology has entered into a clinical trial collaboration and supply agreement with us pharma major Eli Lilly to evaluate the combination of ALX148, a next generation CD47 blocker, and Cyramza (ramucirumab), Lilly’s anti-VEGFR2 antibody, for the treatment of patients with HER2-positive gastric cancer or gastroesophageal junction cancer. 10 June 2021
Biotechnology
Singapore-based clinical-stage biotech Hummingbird Bioscience, which just last month closed a $125 million financing round, has announced a strategic partnership with Asian genomic sequencing and bioinformatics company Novogene. 10 June 2021
Biotechnology
USA-based drug developer Lyra Therapeutics saw its shares gain more than 14% to $9.00 in pre-market trading today, as it announced the positive outcome of the company’s end-of-Phase II meeting with the Food and Drug Administration, establishing the key elements of the upcoming Phase III study for LYR-210, the company’s lead product candidate for the treatment of chronic rhinosinusitis. 9 June 2021
Biotechnology
The launch of Alcyone Therapeutics, a biotech focused on developing gene therapies for central nervous system (CNS) disorders, has been announced. 9 June 2021
Biotechnology
Privately-held Dutch biotech Byondis has announced positive top-line results from the Phase III TULIP study of antibody-drug conjugate (ADC) trastuzumab duocarmazine. 9 June 2021
Biotechnology
Shares of US biotech bluebird bio jumped more than 7% pre-market today, after it announced that the US Food and Drug Administration had lifted the clinical holds on several studies with its gene therapy LentiGlobin. 7 June 2021
Biotechnology
US immuno-dermatology specialist biotech Dermavant Sciences, a subsidiary of Roivant Sciences, has entered into a $160 million revenue interest purchase and sale agreement for its investigational product tapinarof with three participants that include Marathon Asset Management, NovaQuest Capital Management and a third institutional investor located in Boston. 7 June 2021
Biotechnology
The US Food and Drug Administration on Friday approved Ryplazim (plasminogen, human-tvmh) for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia) through Canada-based Liminal BioSciences’ subsidiary Prometic Biotherapeutics, holder of the biological license application (BLA) for Ryplazim. 7 June 2021
Biotechnology
UK antibody drug conjugate (ADC) company Iksuda Therapeutics (Iksuda) today announced it has completed a $47 million (~£34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners 7 June 2021
Biotechnology
Australian biotech Immutep Limited saw its shares rise 10% to A$5.56, after it announced a new collaboration and supply agreement with Germany’s Merck KGaA for a Phase I/IIa clinical trial in patients with solid tumors, called INSIGHT-005. 3 June 2021
Biotechnology
US drug developer Lyra Therapeutics’ shares were up 4.7% at $7.99 in morning trading, after it announced a strategic partnership and exclusive license agreement with Sino-American biotech LianBio for the development and commercialization of LYR-210 in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand. 2 June 2021
Biotechnology
US biotech Corbus Pharmaceuticals today announced the expansion of its portfolio into immuno-oncology through licensing deals for two new monoclonal antibodies (MAbs), CRB-601 (a high potency anti-avb8 MAb) and CRB-602 (anti-avb6/avb8 MAb), that target integrins to inhibit activation of transforming growth factor β (TGFβ), from the University of California San Francisco and Panorama Research. 1 June 2021
Biotechnology
Heartseed and Danish pharma major Novo Nordisk have entered into an exclusive worldwide collaboration and licence agreement for development, manufacturing and commercialization of the Japanese start-up’s lead asset, HS-001. 1 June 2021
Biotechnology
Californian cytokine storm syndrome specialist Humanigen on Friday announced it has submitted an application to the US Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for lenzilumab for the treatment of patients hospitalized with COVID-19. 1 June 2021
Biotechnology
The US Food and Drug Administration has granted accelerated approval to Truseltiq (infigratinib), a kinase inhibitor for adults with previously treated, unresectable locally-advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. 29 May 2021
Pharmaceutical
USA-headquartered digital medicines company Akili Interactive, maker of EndeavorRx, the first and only prescription video game treatment, today announced $160 million in combined equity and debt financing. 26 May 2021
Biotechnology
French clinical-stage biotech Abivax has released positive Phase IIb clinical induction and preliminary maintenance study results. 254 patients with moderate to severe ulcerative colitis (UC) were treated with ABX464, a small molecule for once-daily administration with a first-in-class mechanism of action. 26 May 2021
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze